Crinetics Pharmaceuticals (CRNX) Competitors $54.72 -4.94 (-8.28%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CRNX vs. IONS, AVDL, BCYC, AGLE, MRNA, VTRS, SMMT, GMAB, PCVX, and RDYShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Ionis Pharmaceuticals (IONS), Avadel Pharmaceuticals (AVDL), Bicycle Therapeutics (BCYC), Aeglea BioTherapeutics (AGLE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Vaxcyte (PCVX), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "medical" sector. Crinetics Pharmaceuticals vs. Ionis Pharmaceuticals Avadel Pharmaceuticals Bicycle Therapeutics Aeglea BioTherapeutics Moderna Viatris Summit Therapeutics Genmab A/S Vaxcyte Dr. Reddy's Laboratories Ionis Pharmaceuticals (NASDAQ:IONS) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Does the media refer more to IONS or CRNX? In the previous week, Crinetics Pharmaceuticals had 15 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 32 mentions for Crinetics Pharmaceuticals and 17 mentions for Ionis Pharmaceuticals. Crinetics Pharmaceuticals' average media sentiment score of 0.16 beat Ionis Pharmaceuticals' score of 0.13 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Crinetics Pharmaceuticals 4 Very Positive mention(s) 4 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, IONS or CRNX? Crinetics Pharmaceuticals has lower revenue, but higher earnings than Ionis Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIonis Pharmaceuticals$788M6.88-$366.29M-$2.44-14.07Crinetics Pharmaceuticals$4.01M1,265.52-$214.53M-$3.73-14.67 Do analysts recommend IONS or CRNX? Ionis Pharmaceuticals presently has a consensus target price of $60.65, suggesting a potential upside of 76.61%. Crinetics Pharmaceuticals has a consensus target price of $70.18, suggesting a potential upside of 28.26%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ionis Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.68Crinetics Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Does the MarketBeat Community believe in IONS or CRNX? Ionis Pharmaceuticals received 539 more outperform votes than Crinetics Pharmaceuticals when rated by MarketBeat users. However, 69.06% of users gave Crinetics Pharmaceuticals an outperform vote while only 60.21% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIonis PharmaceuticalsOutperform Votes69360.21% Underperform Votes45839.79% Crinetics PharmaceuticalsOutperform Votes15469.06% Underperform Votes6930.94% Do institutionals & insiders believe in IONS or CRNX? 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 6.0% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is IONS or CRNX more profitable? Crinetics Pharmaceuticals has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -44.58%. Crinetics Pharmaceuticals' return on equity of -36.12% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ionis Pharmaceuticals-44.58% -88.98% -12.42% Crinetics Pharmaceuticals N/A -36.12%-31.89% Which has more volatility & risk, IONS or CRNX? Ionis Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Crinetics Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. SummaryCrinetics Pharmaceuticals beats Ionis Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Ad Genesis Gold GroupTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.07B$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E Ratio-14.674.8266.7313.27Price / Sales1,265.52374.171,265.2981.14Price / CashN/A51.8140.2135.77Price / Book6.099.636.455.92Net Income-$214.53M$154.43M$119.73M$225.73M7 Day Performance-9.84%-9.46%-5.13%-1.34%1 Month Performance-7.13%-7.27%-2.71%1.15%1 Year Performance82.46%28.13%31.08%24.02% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals3.5501 of 5 stars$54.72-8.3%$70.18+28.3%+93.1%$5.07B$4.01M-14.67210Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageIONSIonis Pharmaceuticals4.2698 of 5 stars$37.77-2.9%N/A-29.3%$5.96B$803.07M-15.48800Analyst DowngradeInsider SellingShort Interest ↑News CoverageAVDLAvadel Pharmaceuticals2.6305 of 5 stars$13.15-19.3%N/A+1.8%$1.27B$95.15M-11.24154Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownHigh Trading VolumeBCYCBicycle Therapeutics2.8616 of 5 stars$23.42-3.7%N/A+55.8%$1.11B$26.98M-7.12240Insider SellingShort Interest ↑AGLEAeglea BioTherapeuticsN/AN/AN/AN/A$48.64M$2.33M-0.1669Analyst ForecastMRNAModerna4.5631 of 5 stars$43.47+1.7%N/A-51.9%$16.71B$6.85B-7.475,600Analyst ForecastOptions VolumeGap DownHigh Trading VolumeVTRSViatris1.3727 of 5 stars$12.93-1.2%N/A+39.9%$15.43B$15.05B-17.4738,000Insider SellingSMMTSummit Therapeutics2.1973 of 5 stars$20.76-4.6%N/A+884.4%$15.31B$700,000.00-74.14105Gap UpGMABGenmab A/S4.426 of 5 stars$22.47-3.1%N/A-35.6%$14.87B$19.84B21.822,204Short Interest ↑High Trading VolumePCVXVaxcyte3.3295 of 5 stars$99.38-4.1%N/A+73.3%$12.39BN/A-21.60160News CoverageRDYDr. Reddy's Laboratories1.3344 of 5 stars$14.76-1.6%N/A+6.7%$12.32B$299.87B23.5827,048Analyst DowngradeShort Interest ↑ Related Companies and Tools Related Companies Ionis Pharmaceuticals Competitors Avadel Pharmaceuticals Competitors Bicycle Therapeutics Competitors Aeglea BioTherapeutics Competitors Moderna Competitors Viatris Competitors Summit Therapeutics Competitors Genmab A/S Competitors Vaxcyte Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRNX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
